All Clarivate websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
Researchers from Carisma Therapeutics Inc. have provided details on the discovery and preclinical evaluation of a novel mesothelin-targeting chimeric antigen receptor macrophage (CAR-M), CT-1119, being developed as a potential solid tumor immunotherapy candidate.
Investigators at the University of Copenhagen and affiliated organizations presented data from a study that aimed to validate differentially expressed genes (DEGs) in mesial temporal lobe epilepsy (mTLE) as potential new targets.